Uroplasty (NYSE: UPI) was upgraded by equities research analysts at JMP Securities from a “market perform” rating to an “outperform” rating in a research note issued to investors on Friday. The firm currently has a $6.00 price target on the stock, up from their previous price target of $5.60.
UPI has been the subject of a number of other recent research reports. Analysts at Roth Capital upgraded shares of Uroplasty from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday, May 22nd. Separately, analysts at Dougherty & Co cut their price target on shares of Uroplasty from $6.50 to $5.00 in a research note to investors on Friday, March 30th. They now have a “buy” rating on the stock. Finally, analysts at Craig Hallum initiated coverage on shares of Uroplasty in a research note to investors on Tuesday, March 27th. They set a “buy” rating on the stock.
Uroplasty traded up 24.78% on Friday, hitting $4.18. The company’s market cap is $87.0 million.
Uroplasty, Inc. is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions.